CSBio CSBio

X
[{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen inks next Commercial GlymaxX\u00ae License with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ProBioGen"},{"orgOrder":0,"company":"T-knife","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"T-knife"},{"orgOrder":0,"company":"Cevec","sponsor":"Rznomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec and Rznomics Sign License Agreement for THE Use of CAP\u00ae Technology inManufacturing of Adenoviral Vectors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cevec"},{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Supply of Rhenium-188","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OncoBeta"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MorphoSys"},{"orgOrder":0,"company":"Labor Dr. Merk","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Labor Dr. Merk"},{"orgOrder":0,"company":"ProBioGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen Licenses GlymaxX\u00ae Technology to AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ProBioGen"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Medigene","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene Enters Cooperative Research and Development Agreement with the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Medigene"},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,022.7 million","upfrontCash":"$22.7 million","newsHeadline":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tubulis"}]

Find Novel Oncology Drugs in Clinical Development in GERMANY

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumors.

            Lead Product(s): Antibody-drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: $1,022.7 million Upfront Cash: $22.7 million

            Deal Type: Licensing Agreement April 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The companies will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors in T cell-based Therapy.

            Lead Product(s): T cell-based Therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: National Cancer Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BWXT Medical plans to utilize its deep relationships with strategic partner Bayer in irradiation services and development of Actinium-225 (Ac-225). Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).

            Lead Product(s): Actinium-225

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: BWXT Medical Ltd.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The unique advantage of the GlymaxX® technology is that a single GlymaxX® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level.

            Lead Product(s): Afucosylated antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus with modified glycoprotein platform and cancer vaccines platforms.

            Lead Product(s): Modified Oncolytic virus

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, the companies plan to initiate a Phase 1/2 study evaluating the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL.

            Lead Product(s): Plamotamab,Tafasitamab,Lenalidomide

            Therapeutic Area: Oncology Product Name: XmAb 13676

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Xencor

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.

            Lead Product(s): Rhenium-188

            Therapeutic Area: Oncology Product Name: Rhenium-188

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: NanoMab Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Rznomics will use CEVEC’s cell line technology in combination with Rznomics’ proprietary trans-splicing ribozyme technology for manufacturing of gene therapies targeting various cancer indications.

            Lead Product(s): RCA-free adenoviral vectors

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Rznomics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Catalent will undertake transfer of T-knife´s platform process for T-cell receptor-based cell therapy at its site in Gosselies, Belgium, with the goal of manufacturing clinical batches for European trials in 2021.

            Lead Product(s): T-cell receptor-based cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Catalent Pharma Solutions

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.

            Lead Product(s): GlymaxX

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY